Skip to main content
NASDAQ:CDTX

Cidara Therapeutics Competitors

$2.00
-0.01 (-0.50 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.95
$2.04
50-Day Range
$1.87
$2.70
52-Week Range
$1.76
$4.45
Volume479,226 shs
Average Volume860,418 shs
Market Capitalization$96.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Competitors

Cidara Therapeutics (NASDAQ:CDTX) Vs. SURF, OPT, ADVM, SQZ, FUSN, and AUTL

Should you be buying CDTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Cidara Therapeutics, including Surface Oncology (SURF), Opthea (OPT), Adverum Biotechnologies (ADVM), SQZ Biotechnologies (SQZ), Fusion Pharmaceuticals (FUSN), and Autolus Therapeutics (AUTL).

Cidara Therapeutics (NASDAQ:CDTX) and Surface Oncology (NASDAQ:SURF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Cidara Therapeutics and Surface Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cidara Therapeutics00503.00
Surface Oncology02502.71

Cidara Therapeutics presently has a consensus target price of $7.20, indicating a potential upside of 260.00%. Surface Oncology has a consensus target price of $14.1667, indicating a potential upside of 67.45%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cidara Therapeutics is more favorable than Surface Oncology.

Insider and Institutional Ownership

60.1% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 52.0% of Surface Oncology shares are held by institutional investors. 6.8% of Cidara Therapeutics shares are held by insiders. Comparatively, 35.0% of Surface Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cidara Therapeutics and Surface Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cidara Therapeutics$20.92 million4.62$-41,090,000.00($1.41)-1.42
Surface Oncology$15.36 million24.32$-54,790,000.00($1.97)-4.37

Cidara Therapeutics has higher revenue and earnings than Surface Oncology. Surface Oncology is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cidara Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500.

Profitability

This table compares Cidara Therapeutics and Surface Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cidara Therapeutics-662.48%-165.58%-92.73%
Surface OncologyN/A-29.77%-17.05%

Summary

Cidara Therapeutics beats Surface Oncology on 7 of the 13 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Valuation & Earnings

This table compares Opthea and Cidara Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptheaN/AN/AN/AN/AN/A
Cidara Therapeutics$20.92 million4.62$-41,090,000.00($1.41)-1.42

Opthea has higher earnings, but lower revenue than Cidara Therapeutics.

Institutional & Insider Ownership

60.1% of Cidara Therapeutics shares are held by institutional investors. 6.8% of Cidara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Opthea and Cidara Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opthea01502.83
Cidara Therapeutics00503.00

Opthea presently has a consensus price target of $36.00, indicating a potential upside of 334.35%. Cidara Therapeutics has a consensus price target of $7.20, indicating a potential upside of 260.00%. Given Opthea's higher probable upside, equities research analysts clearly believe Opthea is more favorable than Cidara Therapeutics.

Profitability

This table compares Opthea and Cidara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptheaN/AN/AN/A
Cidara Therapeutics-662.48%-165.58%-92.73%

Adverum Biotechnologies (NASDAQ:ADVM) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares Adverum Biotechnologies and Cidara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Cidara Therapeutics-662.48%-165.58%-92.73%

Earnings and Valuation

This table compares Adverum Biotechnologies and Cidara Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.001,402.43$-64,490,000.00($1.01)-3.54
Cidara Therapeutics$20.92 million4.62$-41,090,000.00($1.41)-1.42

Cidara Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Adverum Biotechnologies has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Insider & Institutional Ownership

97.4% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 60.1% of Cidara Therapeutics shares are owned by institutional investors. 12.4% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 6.8% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Adverum Biotechnologies and Cidara Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies08202.20
Cidara Therapeutics00503.00

Adverum Biotechnologies presently has a consensus price target of $14.1250, suggesting a potential upside of 294.55%. Cidara Therapeutics has a consensus price target of $7.20, suggesting a potential upside of 260.00%. Given Adverum Biotechnologies' higher possible upside, research analysts clearly believe Adverum Biotechnologies is more favorable than Cidara Therapeutics.

Summary

Adverum Biotechnologies beats Cidara Therapeutics on 9 of the 14 factors compared between the two stocks.

SQZ Biotechnologies (NYSE:SQZ) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares SQZ Biotechnologies and Cidara Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ BiotechnologiesN/AN/AN/AN/AN/A
Cidara Therapeutics$20.92 million4.62$-41,090,000.00($1.41)-1.42

SQZ Biotechnologies has higher earnings, but lower revenue than Cidara Therapeutics.

Institutional & Insider Ownership

60.1% of Cidara Therapeutics shares are held by institutional investors. 6.8% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and Cidara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQZ BiotechnologiesN/AN/AN/A
Cidara Therapeutics-662.48%-165.58%-92.73%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for SQZ Biotechnologies and Cidara Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQZ Biotechnologies00503.00
Cidara Therapeutics00503.00

SQZ Biotechnologies presently has a consensus price target of $38.3333, suggesting a potential upside of 207.40%. Cidara Therapeutics has a consensus price target of $7.20, suggesting a potential upside of 260.00%. Given Cidara Therapeutics' higher probable upside, analysts plainly believe Cidara Therapeutics is more favorable than SQZ Biotechnologies.

Summary

Cidara Therapeutics beats SQZ Biotechnologies on 4 of the 7 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Fusion Pharmaceuticals and Cidara Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
Cidara Therapeutics00503.00

Fusion Pharmaceuticals presently has a consensus target price of $23.6667, indicating a potential upside of 189.68%. Cidara Therapeutics has a consensus target price of $7.20, indicating a potential upside of 260.00%. Given Cidara Therapeutics' higher possible upside, analysts plainly believe Cidara Therapeutics is more favorable than Fusion Pharmaceuticals.

Institutional and Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.1% of Cidara Therapeutics shares are owned by institutional investors. 6.8% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Fusion Pharmaceuticals and Cidara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
Cidara Therapeutics-662.48%-165.58%-92.73%

Earnings & Valuation

This table compares Fusion Pharmaceuticals and Cidara Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
Cidara Therapeutics$20.92 million4.62$-41,090,000.00($1.41)-1.42

Fusion Pharmaceuticals has higher earnings, but lower revenue than Cidara Therapeutics.

Summary

Fusion Pharmaceuticals beats Cidara Therapeutics on 5 of the 8 factors compared between the two stocks.

Cidara Therapeutics (NASDAQ:CDTX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Cidara Therapeutics and Autolus Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cidara Therapeutics00503.00
Autolus Therapeutics02602.75

Cidara Therapeutics presently has a consensus target price of $7.20, indicating a potential upside of 260.00%. Autolus Therapeutics has a consensus target price of $21.00, indicating a potential upside of 235.46%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cidara Therapeutics is more favorable than Autolus Therapeutics.

Volatility and Risk

Cidara Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cidara Therapeutics and Autolus Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cidara Therapeutics$20.92 million4.62$-41,090,000.00($1.41)-1.42
Autolus Therapeutics$2.91 million111.71$-123,850,000.00($2.88)-2.16

Cidara Therapeutics has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cidara Therapeutics and Autolus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cidara Therapeutics-662.48%-165.58%-92.73%
Autolus Therapeutics-8,652.90%-54.01%-44.19%

Insider and Institutional Ownership

60.1% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are held by institutional investors. 6.8% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cidara Therapeutics beats Autolus Therapeutics on 9 of the 14 factors compared between the two stocks.


Cidara Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Surface Oncology logo
SURF
Surface Oncology
1.4$8.60-1.6%$367.41 million$15.36 million-13.03Analyst Report
Opthea logo
OPT
Opthea
1.5$8.29-2.1%$360.19 millionN/A0.00News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$3.58-0.6%$350.61 million$250,000.00-2.82Analyst Upgrade
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.47-4.7%$347.69 millionN/A0.00
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.4$8.17-0.1%$346.87 millionN/A0.00Earnings Announcement
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.21-0.8%$327.69 million$2.91 million-2.16
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.45-1.2%$317.31 million$250,000.00-3.02Analyst Report
Innate Pharma logo
IPHA
Innate Pharma
1.1$3.97-1.3%$313.59 million$96.12 million-11.68
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.7$8.60-1.7%$308.35 millionN/A0.00Earnings Announcement
High Trading Volume
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.20-0.2%$278.40 millionN/A-3.37Analyst Downgrade
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$9.34-1.0%$232.83 millionN/A-6.82
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.76-1.7%$209.81 million$29.35 million-2.05Earnings Announcement
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.49-3.4%$201.31 million$4.13 million-3.31Earnings Announcement
Analyst Report
Genfit logo
GNFT
Genfit
1.3$4.10-0.2%$194.54 million$45.88 million-2.08
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.49-1.9%$177.18 millionN/A-2.34News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.54-0.4%$171.29 million$104.39 million-2.77
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.32-0.2%$164.34 millionN/A-7.71Earnings Announcement
Analyst Revision
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.84-1.0%$164.17 million$2.45 million-1.80Earnings Announcement
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.32-2.7%$153.07 millionN/A-4.42
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.72-0.4%$151.80 millionN/A-2.95
INmune Bio logo
INMB
INmune Bio
1.5$10.05-2.7%$150.08 millionN/A-10.36
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.60-4.1%$142.69 millionN/A-1.68Gap Down
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.30-7.0%$136.24 millionN/A0.00Earnings Announcement
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.00-0.0%$132.41 million$2.33 million0.00Earnings Announcement
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.80-0.4%$131.76 million$32.12 million-75.38Analyst Downgrade
Axcella Health logo
AXLA
Axcella Health
1.6$3.37-0.3%$127.12 millionN/A-1.57
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.36-0.6%$122.03 millionN/A-3.20
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.23-1.8%$121.39 millionN/A-1.54
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.92-2.6%$121.25 million$20,000.000.00
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.00-4.5%$112.51 millionN/A0.00Gap Up
PolarityTE logo
PTE
PolarityTE
1.5$0.93-1.8%$110.33 million$5.65 million-0.56Earnings Announcement
Gap Down
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.31-3.2%$104.54 millionN/A0.00
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.75-0.3%$102.93 million$23.05 million-1.67
Dyadic International logo
DYAI
Dyadic International
1.3$3.50-6.6%$96.44 million$1.68 million-10.29Gap Down
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.01-0.0%$96.12 million$140,000.000.00Earnings Announcement
Upcoming Earnings
News Coverage
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.18-0.3%$95.80 million$3 million-1.99
ENTX
Entera Bio
1.2$3.03-3.3%$71.81 million$240,000.00-4.46Upcoming Earnings
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$3.88-3.1%$67.11 million$10,000.000.00Upcoming Earnings
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.14-3.5%$65.68 millionN/A-0.90
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.66-0.5%$58.60 million$420,000.00-1.38Earnings Announcement
Analyst Report
BioCardia logo
BCDA
BioCardia
1.2$3.44-0.3%$57.77 million$710,000.00-1.77Earnings Announcement
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.66-1.4%$55.00 million$10,000.000.00News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.81-2.5%$54.05 million$7.92 million-0.34Earnings Announcement
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.05-2.9%$52.54 million$1.45 million-0.37
Organovo logo
ONVO
Organovo
0.7$7.25-1.4%$50.89 million$2.20 million0.00Gap Up
Microbot Medical logo
MBOT
Microbot Medical
1.3$6.73-0.1%$47.84 millionN/A0.00Upcoming Earnings
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$6.48-5.9%$44.73 millionN/A0.00News Coverage
Gap Down
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$1.68-4.8%$44.11 million$200,000.00-0.70Earnings Announcement
Gap Down
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.43-1.4%$42.04 million$192.41 million0.80
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$2.85-0.7%$32.36 millionN/A-0.94
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.